IRIS Accounts Production v23.3.1.45 08605170 Board of Directors 1.7.22 30.6.23 30.6.23 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh086051702022-06-30086051702023-06-30086051702022-07-012023-06-30086051702021-06-30086051702021-07-012022-06-30086051702022-06-3008605170ns10:Originalns15:EnglandWales2022-07-012023-06-3008605170ns14:PoundSterlingns10:Original2022-07-012023-06-3008605170ns10:Originalns10:Director12022-07-012023-06-3008605170ns10:Original2022-07-012023-06-3008605170ns10:Original2023-06-3008605170ns10:Originalns10:PrivateLimitedCompanyLtd2022-07-012023-06-3008605170ns10:Originalns10:SmallEntities2022-07-012023-06-3008605170ns10:Originalns10:AuditExempt-NoAccountantsReport2022-07-012023-06-3008605170ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-07-012023-06-3008605170ns10:SmallCompaniesRegimeForAccountsns10:Original2022-07-012023-06-3008605170ns10:Originalns10:FullAccounts2022-07-012023-06-3008605170ns10:Originalns10:OrdinaryShareClass12022-07-012023-06-3008605170ns10:Originalns10:Director42022-07-012023-06-3008605170ns10:Originalns10:RegisteredOffice2022-07-012023-06-3008605170ns10:Original2022-06-3008605170ns10:Originalns5:CurrentFinancialInstruments2023-06-3008605170ns10:Originalns5:CurrentFinancialInstruments2022-06-3008605170ns5:ShareCapitalns10:Original2023-06-3008605170ns5:ShareCapitalns10:Original2022-06-3008605170ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-06-3008605170ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-06-3008605170ns10:Original2021-07-012022-06-3008605170ns10:Originalns5:CostValuation2022-06-3008605170ns10:Originalns10:OrdinaryShareClass12023-06-3008605170ns10:Original12022-07-012023-06-30
REGISTERED NUMBER: 08605170 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2023

FOR

BIOINDUCTION MEDICAL LIMITED

BIOINDUCTION MEDICAL LIMITED (REGISTERED NUMBER: 08605170)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


BIOINDUCTION MEDICAL LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 30 JUNE 2023







DIRECTORS: MR T Denison
Mr A H W Crawley





REGISTERED OFFICE: 178 - 180 Hotwell Road
Clifton
Bristol
BS8 4RP





REGISTERED NUMBER: 08605170 (England and Wales)





ACCOUNTANTS: Lawes & Co
Boyce's Building
40-42 Regent Street
Clifton
Bristol
BS8 4HU

BIOINDUCTION MEDICAL LIMITED (REGISTERED NUMBER: 08605170)

BALANCE SHEET
30 JUNE 2023

30.6.23 30.6.22
Notes £    £    £    £   
FIXED ASSETS
Investments 4 402,000 402,000

CURRENT ASSETS
Cash at bank 105 82

CREDITORS
Amounts falling due within one year 5 8,270 7,940
NET CURRENT LIABILITIES (8,165 ) (7,858 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

393,835

394,142

CAPITAL AND RESERVES
Called up share capital 6 100 100
Retained earnings 393,735 394,042
SHAREHOLDERS' FUNDS 393,835 394,142

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

BIOINDUCTION MEDICAL LIMITED (REGISTERED NUMBER: 08605170)

BALANCE SHEET - continued
30 JUNE 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 9 February 2024 and were signed on its behalf by:





Mr A H W Crawley - Director


BIOINDUCTION MEDICAL LIMITED (REGISTERED NUMBER: 08605170)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023

1. STATUTORY INFORMATION

Bioinduction Medical Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2022 - 2 ) .

4. FIXED ASSET INVESTMENTS
Shares in
group
undertaki
£   
COST
At 1 July 2022
and 30 June 2023 402,000
NET BOOK VALUE
At 30 June 2023 402,000
At 30 June 2022 402,000

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.6.23 30.6.22
£    £   
Amounts owed to group undertakings 2,828 2,384
Amounts owed to associates 4,302 3,636
Accrued expenses 1,140 1,920
8,270 7,940

BIOINDUCTION MEDICAL LIMITED (REGISTERED NUMBER: 08605170)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 JUNE 2023

6. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30.6.23 30.6.22
value: £    £   
100 Ordinary £1 100 100

7. RELATED PARTY DISCLOSURES

At the year end the company owed £2,828 (2022: £2,384) to Finetech Medical Limited. Bioinduction Medical Limited is the sole shareholder of Finetech Medical Limited.

At the year end the company owed Bioinduction Limited £4,302 (2022: £3,636). Bioinduction Limited is the majority shareholder of Bioinduction Medical Limited.

8. POST BALANCE SHEET EVENTS

The entire company's share capital was acquired by Amber Therapeutics Ltd on 25 July 2023.

9. ULTIMATE CONTROLLING PARTY

There is no ultimate controlling party.